| Product NDC: | 0378-0460 |
| Proprietary Name: | MAXZIDE |
| Non Proprietary Name: | maxzide |
| Active Ingredient(s): | 50; 75 mg/1; mg/1 & nbsp; maxzide |
| Administration Route(s): | ORAL |
| Dosage Form(s): | TABLET |
| Coding System: | National Drug Codes(NDC) |
| Product NDC: | 0378-0460 |
| Labeler Name: | Mylan Pharmaceuticals Inc. |
| Product Type: | HUMAN PRESCRIPTION DRUG |
| FDA Application Number: | NDA019129 |
| Marketing Category: | NDA |
| Start Marketing Date: | 19880513 |
| Package NDC: | 0378-0460-01 |
| Package Description: | 100 TABLET in 1 BOTTLE, PLASTIC (0378-0460-01) |
| NDC Code | 0378-0460-01 |
| Proprietary Name | MAXZIDE |
| Package Description | 100 TABLET in 1 BOTTLE, PLASTIC (0378-0460-01) |
| Product NDC | 0378-0460 |
| Product Type Name | HUMAN PRESCRIPTION DRUG |
| Non Proprietary Name | maxzide |
| Dosage Form Name | TABLET |
| Route Name | ORAL |
| Start Marketing Date | 19880513 |
| Marketing Category Name | NDA |
| Labeler Name | Mylan Pharmaceuticals Inc. |
| Substance Name | HYDROCHLOROTHIAZIDE; TRIAMTERENE |
| Strength Number | 50; 75 |
| Strength Unit | mg/1; mg/1 |
| Pharmaceutical Classes | Decreased Renal K+ Excretion [PE],Increased Diuresis [PE],Potassium-sparing Diuretic [EPC],Increased Diuresis [PE],Thiazide Diuretic [EPC],Thiazides [Chemical/Ingredient] |